<DOC>
	<DOCNO>NCT02572167</DOCNO>
	<brief_summary>The purpose study assess safety profile antitumor activity brentuximab vedotin administer combination nivolumab patient relapse refractory Hodgkin lymphoma ( HL )</brief_summary>
	<brief_title>A Study Brentuximab Vedotin Combined With Nivolumab Relapsed Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description>This study examine safety profile antitumor activity brentuximab vedotin combine nivolumab . Patients treat four 21-day cycle brentuximab vedotin 1.8 mg/kg nivolumab 3 mg/kg . There 2 part study . In Part 1 , safety combination treatment evaluate Safety Monitoring Committee ( SMC ) prior expansion enrollment evaluate treatment effect Part 2 . Part 2 study characterize safety evaluate antitumor activity brentuximab vedotin combine nivolumab enrol patient recommend dose schedule determine Part 1 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Relapsed refractory Hodgkin lymphoma follow failure standard frontline chemotherapy treatment classical Hodgkin lymphoma Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Previously treat brentuximab vedotin , immuneoncology agent , receive allogeneic autologous stem cell transplant Documented history cerebral vascular event History another invasive malignancy remission least 3 year History progressive multifocal leukoencephalopathy ( PML )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Monomethyl auristatin E</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Autologous stem cell transplant</keyword>
</DOC>